Pediatric Dermatology Unit, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Clin Exp Dermatol. 2018 Jul;43(5):559-565. doi: 10.1111/ced.13391. Epub 2018 Feb 20.
Most cases of paediatric cutaneous mastocytosis (CM) occur before the age of 2 years, and regression occurs in only 67% of children. Given the absence of any specific therapy, CM is usually treated symptomatically. A few publications have reported the beneficial effect of calcineurin inhibitors for CM.
We sought to evaluate the clinical effectiveness and safety profile of topical pimecrolimus cream for the treatment of CM.
We performed a retrospective study of all diagnosed cases of CM treated with topical pimecrolimus 1% cream between 2013 and 2015. All patients were evaluated in a paediatric dermatology unit of a tertiary medical centre. Epidemiological, clinical and treatment data, including effectiveness and safety, were reviewed.
In total, 18 children (11 male, 7 female; age range 3-42 months) with CM were evaluated. Of the 146 treated lesions, 39 (26.7%) disappeared and 98 (67%) faded or developed postinflammatory hyperpigmentation. Of the 119 papular lesions, 24 (16.4%) showed partial flattening and 56 (47%) became macular. Darier sign became negative in 14 (82%) of 17 patients. No topical or systemic complications were observed.
Topical therapy with pimecrolimus 1% cream should be considered in the treatment of CM.
大多数儿童皮肤肥大细胞瘤（CM）发生在 2 岁之前，只有 67%的儿童会自行消退。由于缺乏任何特定的治疗方法，CM 通常采用对症治疗。少数文献报道钙调神经磷酸酶抑制剂对 CM 有效。
我们旨在评估他克莫司乳膏（商品名：普特彼）外用治疗 CM 的临床疗效和安全性。
我们对 2013 年至 2015 年间在一家三级医疗中心的儿科皮肤科接受他克莫司乳膏（1%浓度）治疗的所有确诊 CM 病例进行了回顾性研究。所有患者均在该儿科皮肤科接受评估。回顾性分析了流行病学、临床和治疗数据，包括有效性和安全性。
共评估了 18 例 CM 患儿（11 名男性，7 名女性；年龄 3-42 个月）。在 146 个接受治疗的皮损中，39 个（26.7%）消失，98 个（67%）褪色或出现炎症后色素沉着。在 119 个丘疹性皮损中，24 个（16.4%）部分变平，56 个（47%）变成斑片状。17 例患者中的 14 例（82%）Darier 征变为阴性。未观察到局部或全身并发症。
他克莫司乳膏（1%浓度）外用治疗 CM 应被考虑。
